Background Babies born preterm are at an increased risk of dying in the first weeks of life,
and those who survive have a higher rate of cerebral palsy (CP) compared with babies born …

Despite improvements in perinatal care, preterm birth still occurs regularly and the
associated brain injury and adverse neurological outcomes remain a persistent challenge …

Objective The objective is to provide guidelines for the use of antenatal magnesium sulphate
for fetal neuroprotection of the preterm infant. Options Antenatal magnesium sulphate …

Importance Intravenous magnesium sulfate administered to pregnant individuals before birth
at less than 30 weeks' gestation reduces the risk of death and cerebral palsy in their …

Background The effectiveness of antenatal magnesium sulphate for neuroprotection of the
fetus, infant, and child prior to very preterm birth, when given to women considered at risk of …

METHODS OF STUDY SELECTION: Randomized controlled trials comparing magnesium
sulfate with placebo/other treatment in patients at risk of preterm delivery were evaluated for …

Background Ordinary meta‐analyses indicate that magnesium sulphate (MgSO4) treatment
in women at imminent risk for preterm delivery decreases the offspring's risk of cerebral …

We conducted a systematic review and metaanalysis of randomized controlled trials to
determine whether magnesium sulfate administered to women at risk of preterm delivery …

Background Epidemiological and basic science evidence suggests that magnesium
sulphate before birth may be neuroprotective for the fetus. Objectives To assess the effects …

Background Research suggests that fetal exposure to magnesium sulfate before preterm
birth might reduce the risk of cerebral palsy. Methods In this multicenter, placebo-controlled …